Preliminary experiments in this study revealed that Ses treatment led to a decrease in hepatic mRNA expression of NLRC4 in NASH mice, whereas no significant changes were observed in the mRNA expression levels of NLRP1, NLRP3 and NLRP6 (data not shown). The gene discussed is NLRC4; the disease is metabolic dysfunction-associated steatohepatitis.